Seminars in Diagnostic Pathology
Volume 26, Issue 1 , Pages 38-48 , February 2009

The effect of complimentary and alternative medicine products on laboratory testing

  • Robert Rosecrans, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Robert Rosecrans, PhD, NorthShore University HealthSystem, Highland Park Hospital, Department of Pathology and Laboratory Medicine, 777 Park Avenue West, Highland Park, IL 60035
    • ,
  • James C. Dohnal, PhD, MSIS, DABCC

References 

  1. Miller LG. Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200–2211
  2. FDA/CFSAN Dietary Supplement Health and Education Act of 1994. http://www.cfsan.fda.gov/∼dms/dietsupp.html
  3. Eisenberg DM, Davis RB, Ettner S, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up survey. J Am Med Assoc. 1998;280:1569–1575
  4. National Center for Complementary and Alternative Medicine. National Institutes oh Health (The Use of Complimentary and Alternative Medicine in the United States). http://nccam.nih.gov./news/camsurvey_fs1.htm#spend
  5. van der Sluijs C. Women's health during mid-life survey: the use of complementary and alternative medicine by symptomatic women transitioning through menopause in Sydney. Menopause. 2007;14:397–403
  6. Newton KM, Buist DSM, Keenan NL, et al. Use of alternative therapies for menopause symptoms: results of a population-based study. Obstet Gynecol. 2002;100:18–25
  7. Gollschewski S, Anderson D, Skerman H, et al. The use of complementary and alternative medications by menopausal women in South East Queensland. Womens Health Issues. 2004;14:165–171
  8. Norred C. Complementary and alternative medicine use by surgical patients. AORN J. 2002;76:1013–1021
  9. Goldman D, Rogovik AL, Lai D, et al. Potential interactions of drug-natural health products and natural health products-natural health products among children. J Pediatr. 2008;152:521–526
  10. Wilson K, Klein J. Adolescents' use of complementary and alternative medicine. Pediatr Res. 2000;47:13a-13e
  11. Goldman RD, Vohra S. Complementary and alternative medicine use by children visiting a pediatric emergency department. Can J Clin Pharmacol. 2004;11:e245–e256
  12. Dunbabin DW, Tallis GA, Popplewell PY, et al. Lead poisoning from Indian herbal medicine (Ayurveda). Med J Aust. 1992;157:835–836
  13. Saper RB, Kales KN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. J Am Med Assoc. 2004;292:2868–2873
  14. Caldas ED, Machado LL. Cadmium, mercury and lead in medical herbs in Brazil. Food Chem Toxicol. 2004;42:599–603
  15. Huang WF, Wen KC, Hsaio ML, et al. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37:344–350
  16. Lau G, Lo DS, Yao YJ, et al. A fatal case of hepatic failure possibly induced by nitrosofenfluramine: a case report. Med Sci Law. 2004;44:252–263
  17. Lau KK, Lai CK, Chan AYW, et al. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol. 2000;19:385–386
  18. Vander Stricht BL, Parvais QE, Vanhaelen-Fastre RJ, et al. Safer use of traditional remedies (Remedies may contain cocktail of active drugs). Br Med J. 1994;308:1162
  19. Guengerich F. Cytochrome 450 enzymes. In:  Ortiz de Montellano P editors. Cytochrome P450. (ed 2). New York, NY: Plenum Press; 1995;p. 473–575
  20. Guengerich F. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1–17
  21. Sharpiro L, Shear N. Drug interactions: proteins, pumps, and P450s. J Am Acad Dermatol. 2002;4:467–484
  22. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human drug metabolizing cytochrome P450. Ann Biochem. 1997;48:188–190
  23. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–296
  24. Deldoda R, Westlake A. Herbal interactions involving cytochrome P450 enzymes. Toxicol Rev. 2004;23:239–249
  25. Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489–2503
  26. Canigueral S, Tschopp R, Ambrosetti L, et al. The development of herbal medicinal products: quality, safety and efficacy as key factors. Pharmaceut Med. 2008;22:107–118
  27. Stedman C. Herbal heptotoxicity. Semin Liver Dis. 2002;22:195–206
  28. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis. 2007;11:577–596
  29. Estes J, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminate hepatic failure. Arch Surg. 2003;138:852–858
  30. Krusekopf S, Roots I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharamacogenet Genomics. 2005;15:817–829
  31. Barone GW, Gurely BJ, Ketel BL, et al. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 2001;71:330–340
  32. Bauer S, Stromer E, Johne A, et al. Altercation of cyclosporine A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol. 2003;55:203–211
  33. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St. John's wort cyclosporine drug interaction. Clin Pharmocol. 2004;76:330–340
  34. Hebert MF, Park JM, Chen YL, et al. Effects of St. John's wort on tacrolimus pharmacokinetics in healthy volunteers. Clin Pharmacol. 2004;44:89–94
  35. Mai I, Stormer E, Bauer S, et al. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003;18:819–822
  36. Milan F, Arnsten J, Klein R, et al. Use of complementary and alternative medicine in inner-city persons with or at risk of HIV infection. AIDS Patient Care STDS. 2008;22:811–816
  37. Ohno Y, Hiska A. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47:669–680
  38. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Ther Drug Monit. 2008;30:212–217
  39. Draves D, Stieger B, Kullak-Ublick GA, et al. Analysis of hypericin and psuedohypericin content in commercially available St. John's wort preparations. Can J Pharmacol. 2003;10:114–118
  40. Jamieson DD, Duffield PH, Cheng D, et al. Composition of the central nervous system activity of the aqueous and lipid extract of kava. Arch Int Pharmacodyn Ther. 1989;301:66–80
  41. Parkman CA. Another FDA warning: kava supplements. Case Manager. 2002;13:26–28
  42. Rockwell S, Liu Y, Higgins A. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal black cohosh. Breast Cancer Res Treat. 2005;90:233–239
  43. Dodin S, Akoum A, Al-Akoum M. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol. 2007;85:1153–1159
  44. Teas J, Pino S, Critchley A, et al. Variability of iodine content in common commercially available edible seaweed. Thyroid. 2004;14:836–841
  45. Clark CD, Bassett B, Burge MR. Effects of kelp supplementation on thyroid function in euthyroid subjects. Endro Pract. 2003;9:363–369
  46. Amster E, Tiwary A, Schenker MB. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environ Health Perspect. 2007;115:606–608
  47. Elinav E, Chajek-Shaul T. Licorice consumption causing severe hypokalemic paralysis. Mayo Clin Proc. 2003;78:767–768
  48. Cheng T. Herbal interactions with cardiac drugs. Arch Int Med. 2000;160:870–871
  49. Panesar NS. Bufalin and unidentified substance(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem. 1992;38:2155–2256
  50. Dasgupta A, Actor J, Olsen M, et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassyas: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol. 2003;119:298–303
  51. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trail of Ginkgo biloba extract EGb761 in dementia. Demet Geriatr Cogn Disord. 2000;11:230–237
  52. VanDongen M, van Rossum E, Kessels A, et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol. 2003;56:367–376
  53. Vellas B, Grandjean H. Association of Alzheimer's disease onset with ginko biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci. 2003;58:372–377
  54. Esrnst E, Pittler MH. Ginkgo biloba for dementia: a systemic review of double-blind, placebo-controlled trials. Clin Drug Invest. 1999;17:301–308
  55. Bridi R, Crossetti FP, Steffen VM, et al. The antioxidant activity of standardized extract of Ginkgo biloba (EGb761) in rats. Phytother Res. 2001;15:449–451
  56. Ernst E, Stevinson C. Ginkgo biloba for tinnitus: a review. Clin Otolaryngol Allied Sci. 1999;24:164–167
  57. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of Ginkgo biloba special extract Rgb761 on intermittent claudification, a placebo-controlled, double blinded trial. Vasa. 1998;27:105–110
  58. Manocha A, Pillai KK, Husain SZ. Influence of Ginkgo biloba on the effect of anticonvulsants. Indian J Pharmacol. 1966;28:84–87
  59. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163–2175
  60. Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther. 2003;10:247–251
  61. Kaufman DW, Kelly JP, Rosenburg L, et al. Recent patterns of medication use in the ambulant adult population in the United States. J Am Med Assoc. 2002;287:337–344
  62. Volger BK, Pitller MH, Ernst E. The efficacy of ginseng: a systematic review of randomised controlled clinical trials. Eur J Clin Pharmacol. 1999;55:567–575
  63. Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of Ginko biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology. 2000;152:353–361
  64. Ernst E, Pittler MH. Ginko biloba for dementia: a systematic review of double-blinded placebo-controlled trials. Clin Drug Invest. 1999;17:301–308
  65. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a sysmtematic review. Drugs. 2001;61:2163–2175
  66. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002;25:323–344
  67. Johnson ES, Kadam NO, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–573
  68. De Weerdt CJ, Bootsma HPR, Hendricks H. Herbal medicines in migraine prevention: randomized double-blinded placebo controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3:252-230
  69. Pattrick M, Heptinsall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blinded, placebo controlled study. Ann Rheum Dis. 1989;48:547–549
  70. Sumner H, Salan U, Knight DW, et al. Inhibition of 5-lipoxygease and cyclo-oxygenase in leukocytes by Feverfew: involvement of sesquiterpene lactonew and other components. Biochem Pharmacol. 1992;43:704–708
  71. Melchart D, Linde K, Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Alt Comp Med. 1995;1:145–160
  72. Turner RB, Riker DK, Gangemi JD. Ineffectiveness of Echiinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother. 2000;44:1708–1709
  73. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St John's Wort, Ginseng, Echinacea, Saw Palmetto and Kava Ann. Intern Med. 2002;136:42–53
  74. Panesar NS. Bufalin and inidentified substances(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem. 1992;38:2155–2156
  75. Chow L, Johnson M, Wells A, et al. Effect of traditional Chinese medicines Chan-Su, Lu-Shen-Wan, Dan Shen and Asian giseng on serum digoxin measurement by Tina-quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal. 2003;17:22–27
  76. Dasgupta A, Biddle D, Wells A, et al. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference by using monoclonal chemilumiescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol. 2000;114:174–179

PII: S0740-2570(08)00113-5

doi: 10.1053/j.semdp.2008.12.002

Seminars in Diagnostic Pathology
Volume 26, Issue 1 , Pages 38-48 , February 2009

Article Tools

* Image Usage & Resolution